83 FR 5441 - Agency Information Collection Activities; Proposed Collection; Comment Request; Survey on the Occurrence of Foodborne Illness Risk Factors in Selected Institutional Foodservice and Retail Food Stores Facility Types
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 83, Issue 26 (February 7, 2018)
Food and Drug Administration
Federal Register Volume 83, Issue 26 (February 7, 2018)
| Page Range | 5441-5445 | |
| FR Document | 2018-02413 |
[Federal Register Volume 83, Number 26 (Wednesday, February 7, 2018)] [Notices] [Pages 5441-5445] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-02413] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2018-N-0270] Agency Information Collection Activities; Proposed Collection; Comment Request; Survey on the Occurrence of Foodborne Illness Risk Factors in Selected Institutional Foodservice and Retail Food Stores Facility Types AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the ``Survey on the Occurrence of Foodborne Illness Risk Factors in Selected Institutional Foodservice and Retail Food Stores Facility Types.'' DATES: Submit either electronic or written comments on the collection of information by April 9, 2018. ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before April 9, 2018. The https://www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of April 9, 2018. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. Electronic Submissions Submit electronic comments in the following way:Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any [[Page 5442]] confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ``Written/Paper Submissions'' and ``Instructions''). Written/Paper Submissions Submit written/paper submissions as follows: Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ``Instructions.'' Instructions: All submissions received must include the Docket No. FDA-2018-N-0270 for ``Survey on the Occurrence of Foodborne Illness Risk Factors in Selected Institutional Foodservice and Retail Food Stores Facility Types.'' Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ``confidential.'' Any information marked as ``confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.thefederalregister.org/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ``Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, PRAStaff@fda.hhs.gov. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Survey on the Occurrence of Foodborne Illness Risk Factors in Selected Institutional Foodservice and Retail Food Stores Facility Types OMB Control Number 0910-0799--Reinstatement I. Background From 1998 to 2008, FDA's National Retail Food Team conducted a study to measure trends in the occurrence of foodborne illness risk factors, preparation practices, and employee behaviors most commonly reported to the Centers for Disease Control and Prevention as contributing factors to foodborne illness outbreaks at the retail level. Specifically, data was collected by FDA specialists in retail and foodservice establishments at 5-year intervals (1998, 2003, and 2008) to observe and document trends in the occurrence of the following foodborne illness risk factors: Food from Unsafe Sources, Poor Personal Hygiene, Inadequate Cooking, Improper Holding/Time and Temperature, and Contaminated Equipment/Cross-Contamination. FDA developed reports summarizing the findings for each of the three data collection periods (1998, 2003, and 2008) (Refs. 1 to 3). Data from all three data collection periods were analyzed to detect trends in improvement or regression over time and to determine whether progress had been made toward the goal of reducing the occurrence of foodborne illness risk factors in selected retail and foodservice facility types (Ref. 4). Using this 10-year survey as a foundation, in 2013-2014, FDA initiated a new study in full service and fast food restaurants. This study will span 10 years with additional data collections planned for 2017-2018 and 2021-2022. FDA recently completed the baseline data collection in select health care, school, and retail food store facility types in 2015-2016. This proposed study will also span 10 years with additional data collections planned for 2019-2020 (the subject of this information collection request reinstatement) and 2023-2024 (which [[Page 5443]] will be posted in the Federal Register at the next renewal). Table 1--Description of the Facility Types Included in the Survey ------------------------------------------------------------------------ Facility type Description ------------------------------------------------------------------------ Health Care Facilities....... Hospitals and long-term care facilities foodservice operations that prepare meals for highly susceptible populations as defined as follows: Hospitals--A foodservice operation that provides for the nutritional needs of inpatients by preparing meals and transporting them to the patient's room and/or serving meals in a cafeteria setting (meals in the cafeteria may also be served to hospital staff and visitors). Long-term care facilities--A foodservice operation that prepares meals for the residents in a group care living setting such as nursing homes and assisted living facilities. Note: For the purposes of this study, health care facilities that do not prepare or serve food to a highly susceptible population, such as mental health care facilities, are not included in this facility type category. Schools (K-12)............... Foodservice operations that have the primary function of preparing and serving meals for students in one or more grade levels from kindergarten through grade 12. A school foodservice may be part of a public or private institution. Retail Food Stores........... Supermarkets and grocery stores that have a deli department/operation as described as follows: Deli department/operation--Areas in a retail food store where foods, such as luncheon meats and cheeses, are sliced for the customers and where sandwiches and salads are prepared onsite or received from a commissary in bulk containers, portioned, and displayed. Parts of deli operations may include: Salad bars, pizza stations, and other food bars managed by the deli department manager. Areas where other foods are cooked or prepared and offered for sale as ready-to-eat and are managed by the deli department manager. Data will also be collected in the following areas of a supermarket or grocery store, if present: Seafood department/operation-- Areas in a retail food store where seafood is cut, prepared, stored, or displayed for sale to the consumer. In retail food stores where the seafood department is combined with another department (e.g. meat), the data collector will only assess the procedures and practices associated with the processing of seafood. Produce department/operation-- Areas in a retail food store where produce is cut, prepared, stored, or displayed for sale to the consumer. A produce operation may include salad bars or juice stations that are managed by the produce manager. ------------------------------------------------------------------------ The purpose of the study is to: Assist FDA with developing retail food safety initiatives and policies focused on the control of foodborne illness risk factors; Identify retail food safety work plan priorities and allocate resources to enhance retail food safety nationwide; Track changes in the occurrence of foodborne illness risk factors in retail and foodservice establishments over time; and Inform recommendations to the retail and foodservice industry and State, local, tribal, and territorial regulatory professionals on reducing the occurrence of foodborne illness risk factors. The statutory basis for FDA conducting this study is derived from the Public Health Service Act (PHS Act) (42 U.S.C. 243, section 311(a)). Responsibility for carrying out the provisions of the PHS Act relative to food protection was transferred to the Commissioner of Food and Drugs in 1968 (21 CFR 5.10(a)(2) and (4)). Additionally, the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and the Economy Act (31 U.S.C. 1535) require FDA to provide assistance to other Federal, State, and local government bodies. The objectives of the study are to: Identify the least and most often occurring foodborne illness risk factors and food safety behaviors/practices in health care, school, restaurant, and retail food store facility types during each data collection period; Track improvement and/or regression trends in the occurrence of foodborne illness risk factors during the 10-year study period; Examine potential correlations between operational characteristics of food establishments and the control of foodborne illness risk factors; Examine potential correlations between elements within regulatory retail food protection programs and the control of foodborne illness risk factors; and Determine the extent to which food safety management systems and the presence of a certified food protection manager impact the occurrence of foodborne illness risk factors. The methodology to be used for this information collection is described as follows. To obtain a sufficient number of observations to conduct statistically significant analysis, FDA will conduct approximately 400 data collections in each facility type. This sample size has been calculated to provide for sufficient observations to be 95 percent confident that the compliance percentage is within 5 percent of the true compliance percentage. A geographical information system database containing a listing of businesses throughout the United States provides the establishment inventory for the data collections. FDA samples establishments from the inventory based on the descriptions in table 1. FDA does not intend to sample operations that handle only prepackaged food items or conduct low-risk food preparation activities. The ``FDA Food Code'' contains a grouping of establishments by risk, based on the type of food preparation that is normally conducted within the operation (Ref. 5). The intent is to sample establishments that fall under risk categories 2 through 4. FDA has approximately 25 Regional Retail Food Specialists (Specialists) who serve as the data collectors for the 10-year study. The Specialists are geographically dispersed throughout the United States and possess technical expertise in retail food safety and a solid understanding of the operations within each of the facility types to be surveyed. The Specialists are also standardized by FDA's Center for Food Safety and Applied Nutrition personnel in the application and interpretation of the FDA Food Code (Ref. 5). Sampling zones have been established that are equal to the 150-mile radius [[Page 5444]] around a Specialist's home location. The sample is selected randomly from among all eligible establishments located within these sampling zones. The Specialists are generally located in major metropolitan areas (i.e., population centers) across the contiguous United States. Population centers usually contain a large concentration of the establishments FDA intends to sample. Sampling from the 150-mile radius sampling zones around the Specialists' home locations provides three advantages to the study: 1. It provides a cross-section of urban and rural areas from which to sample the eligible establishments. 2. It represents a mix of small, medium, and large regulatory entities having jurisdiction over the eligible establishments. 3. It reduces overnight travel and therefore reduces travel costs incurred by the Agency to collect data. The sample for each data collection period is evenly distributed among Specialists. Given that participation in the study by industry is voluntary and the status of any given randomly selected establishment is subject to change, substitute establishments have been selected for each Specialist for cases where the institutional foodservice, school, or retail food store facility is misclassified, closed, or otherwise unavailable, unable, or unwilling to participate. Prior to conducting the data collection, Specialists contact the State or local jurisdiction that has regulatory responsibility for conducting retail food inspections for the selected establishment. The Specialist verifies with the jurisdiction that the facility has been properly classified for the purposes of the study and is still in operation. The Specialist ascertains whether the selected facility is under legal notice from the State or local regulatory authority. If the selected facility is under legal notice, the Specialist will not conduct a data collection, and a substitute establishment will be used. An invitation is extended to the State or local regulatory authority to accompany the Specialist on the data collection visit. A standard form is used by the Specialists during each data collection. The form is divided into three sections: Section 1-- ``Establishment Information''; Section 2--``Regulatory Authority Information''; and Section 3--``Foodborne Illness Risk Factor and Food Safety Management System Assessment''. The information in Section 1-- ``Establishment Information'' of the form is obtained during an interview with the establishment owner or person in charge by the Specialist and includes a standard set of questions. The information in Section 2--``Regulatory Authority Information'' is obtained during an interview with the program director of the State or local jurisdiction that has regulatory responsibility for conducting inspections for the selected establishment. Section 3 includes three parts: Part A for tabulating the Specialists' observations of the food employees' behaviors and practices in limiting contamination, proliferation, and survival of food safety hazards; Part B for assessing the food safety management system being implemented by the facility; and Part C for assessing the frequency and extent of food employee hand washing. The information in Part A is collected from the Specialists' direct observations of food employee behaviors and practices. Infrequent, nonstandard questions may be asked by the Specialists if clarification is needed on the food safety procedure or practice being observed. The information in Part B is collected by making direct observations and asking follow up questions of facility management to obtain information on the extent to which the food establishment has developed and implemented food safety management systems. The information in Part C is collected by making direct observations of food employee hand washing. No questions are asked in the completion of Section 3, Part C of the form. FDA collects the following information associated with the establishment's identity: Establishment name, street address, city, state, ZIP code, county, industry segment, and facility type. The establishment identifying information is collected to ensure the data collections are not duplicative. Other information related to the nature of the operation, such as seating capacity and number of employees per shift, is also collected. Data will be consolidated and reported in a manner that does not reveal the identity of any establishment included in the study. FDA has collaborated with the Food Protection and Defense Institute to develop a web-based platform in FoodSHIELD to collect, store, and analyze data for the Retail Risk Factor Study. This platform is accessible to State, local, territorial, and tribal regulatory jurisdictions to collect data relevant to their own risk factor studies. For the 2015-2016 data collection, FDA piloted the use of hand-held technology for capturing the data onsite during the data collection visits. The tablets that were made available for the data collections were part of a broader Agency initiative focused on internal uses of hand-held technology. The tablets provided for the data collection presented several technical and logistical challenges and increased the time burden associated with the data collection as compared to the manual entry of data collections. FDA continues to assess the feasibility for fully incorporating use of hand-held technology in subsequent data collections during the 10-year study period. When a data collector is assigned a specific establishment, he or she conducts the data collection and enters the information into the web-based data platform. The interface will support the manual entering of data, as well as the ability to directly enter information in the database via a web browser. The burden for the 2019-2020 data collection is as follows. For each data collection, the respondents will include: (1) The person in charge of the selected facility (whether it be a health care facility, school, or supermarket/grocery store) and (2) the program director (or designated individual) of the respective regulatory authority. To provide the sufficient number of observations needed to conduct a statistically significant analysis of the data, FDA has determined that 400 data collections will be required in each of the three facility types. Therefore, the total number of responses will be 2,400 (400 data collections x 3 facility types x 2 respondents per data collection). The burden associated with the completion of Sections 1 and 3 of the form is specific to the persons in charge of the selected facilities. It includes the time it will take the person in charge to accompany the data collector during the site visit and answer the data collector's questions. The burden related to the completion of Section 2 of the form is specific to the program directors (or designated individuals) of the respective regulatory authorities. It includes the time it will take to answer the data collectors' questions and is the same regardless of the facility type. To calculate the estimate of the hours per response, FDA uses the average data collection duration for similar facility types during the FDA's 2008 Risk Factor Study (Ref. 3) plus an additional 30 minutes (0.5 hours) for the information related to Section 3, Part B of the form. FDA estimates that it will take the persons in charge of health care facility types, schools, and retail food stores 150 minutes (2.5 hours), 120 minutes (2 hours), and 180 minutes (3 hours), respectively, to accompany the data [[Page 5445]] collectors while they complete Sections 1 and 3 of the form. FDA estimates that it will take the program director (or designated individual) of the respective regulatory authority 30 minutes (0.5 hours) to answer the questions related to Section 2 of the form. This burden estimate is unchanged from the last data collection. Hence, the total burden estimate for a data collection in health care facility types is 180 minutes (150 + 30) (3 hours), in schools is 150 minutes (120 + 30) (2.5 hours), and retail food stores is 210 minutes (180 + 30) (3.5 hours). Based on the number of entry refusals from the 2015-2016 baseline data collection, we estimate a refusal rate of 2 percent for the data collections within health care, school, and retail food store facility types. The estimate of the time per non-respondent is 5 minutes (0.08 hours) for the person in charge to listen to the purpose of the visit and provide a verbal refusal of entry. FDA estimates the burden of this collection of information as follows: Table 2--Estimated Annual Reporting Burden 1 -------------------------------------------------------------------------------------------------------------------------------------------------------- Number of Number of Number of responses Total Number of responses Total Average burden per Total Activity respondents per annual non- per non- annual non- response hours respondent responses respondents respondent responses -------------------------------------------------------------------------------------------------------------------------------------------------------- 2019-2020 Data Collection (Health 400 1 400 ........... ........... ........... 2.5....................... 1,000 Care Facilities)--Completion of Sections 1 and 3. 2019-2020 Data Collection 400 1 400 ........... ........... ........... 2......................... 800 (Schools)--Completion of Sections 1 and 3. 2019-2020 Data Collection (Retail 400 1 400 ........... ........... ........... 3......................... 1,200 Food Stores)--Completion of Sections 1 and 3. 2019-2020 Data Collection- 1,200 1 1,200 ........... ........... ........... .5 (30 minutes)........... 600 Completion of Section 2--All Facility Types. 2019-2020 Data Collection-Entry ........... ........... ........... 24 1 24 .08 (5 minutes)........... 1.92 Refusals--All Facility Types. -------------------------------------------------------------------------------------------------------------------- Total.......................... ........... ........... ........... ........... ........... ........... .......................... 3,601.92 -------------------------------------------------------------------------------------------------------------------------------------------------------- 1 There are no capital costs or operating and maintenance costs associated with this collection of information. The burden for this information collection has not changed since the last OMB approval. II. References The following references are on display in the Dockets Management Staff (see ADDRESSES) and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they are also available electronically at https://www.regulations.gov. FDA has verified the website addresses, as of the date this document publishes in the Federal Register, but websites are subject to change over time. 1. ``Report of the FDA Retail Food Program Database of Foodborne Illness Risk Factors'' (2000). Available at: https://wayback.archive-it.org/7993/20170406023019/https://www.fda.gov/downloads/Food/GuidanceRegulation/UCM123546.pdf. 2. ``FDA Report on the Occurrence of Foodborne Illness Risk Factors in Selected Institutional Foodservice, Restaurant, and Retail Food Store Facility Types'' (2004). Available at: https://wayback.archive-it.org/7993/20170406023011/https://www.fda.gov/downloads/Food/GuidanceRegulation/RetailFoodProtection/FoodborneIllnessRiskFactorReduction/UCM423850.pdf. 3. ``FDA Report on the Occurrence of Foodborne Illness Risk Factors in Selected Institutional Foodservice, Restaurant, and Retail Food Store Facility Types'' (2009). Available at: https://wayback.archive-it.org/7993/20170406023004/https://www.fda.gov/Food/GuidanceRegulation/RetailFoodProtection/FoodborneIllnessRiskFactorReduction/ucm224321.htm. 4. FDA National Retail Food Team. ``FDA Trend Analysis Report on the Occurrence of Foodborne Illness Risk Factors in Selected Institutional Foodservice, Restaurant, and Retail Food Store Facility Types (1998-2008).'' Available at: https://wayback.archive-it.org/7993/20170406022950/https://www.fda.gov/Food/GuidanceRegulation/RetailFoodProtection/FoodborneIllnessRiskFactorReduction/ucm223293.htm. 5. ``FDA Food Code.'' Available at: https://www.fda.gov/Food/GuidanceRegulation/RetailFoodProtection/FoodCode/default.htm. Dated: January 31, 2018. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2018-02413 Filed 2-6-18; 8:45 am] BILLING CODE 4164-01-P
![Federal Register / Vol. 83, No. 26 / Wednesday, February 7, 2018 / Notices 5441
product. Although only a portion of a initially submitted on September 19, DEPARTMENT OF HEALTH AND
regulatory review period may count 2014. HUMAN SERVICES
toward the actual amount of extension 3. The date the application was
that the Director of USPTO may award Food and Drug Administration
approved: December 3, 2014. FDA has
(for example, half the testing phase must [Docket No. FDA–2018–N–0270]
verified the applicant’s claim that BLA
be subtracted as well as any time that
125557 was approved on December 3,
may have occurred before the patent Agency Information Collection
was issued), FDA’s determination of the 2014.
Activities; Proposed Collection;
length of a regulatory review period for This determination of the regulatory Comment Request; Survey on the
a human biological product will include review period establishes the maximum Occurrence of Foodborne Illness Risk
all of the testing phase and approval potential length of a patent extension. Factors in Selected Institutional
phase as specified in 35 U.S.C. However, the USPTO applies several Foodservice and Retail Food Stores
156(g)(1)(B). statutory limitations in its calculations Facility Types
FDA has approved for marketing the of the actual period for patent extension.
human biologic product BLINCYTO AGENCY: Food and Drug Administration,
In its applications for patent extension,
(blinatumomab). BLINCYTO is HHS.
this applicant seeks 1,462 or 432 days
indicated for the treatment of ACTION: Notice.
of patent term extension.
Philadelphia chromosome-negative
SUMMARY: The Food and Drug
relapsed or refractory B-cell precuror III. Petitions
Administration (FDA or Agency) is
acute lymphoblastic leukemia. This
Anyone with knowledge that any of announcing an opportunity for public
indication is approved under
the dates as published are incorrect may comment on the proposed collection of
accelerated approval. Continued
submit either electronic or written certain information by the Agency.
approval for this indication may be
comments and, under 21 CFR 60.24, ask Under the Paperwork Reduction Act of
contingent upon verification of clinical
benefit in subsequent trials. Subsequent for a redetermination (see DATES). 1995 (PRA), Federal Agencies are
to this approval, the USPTO received Furthermore, as specified in § 60.30 (21 required to publish notice in the
patent term restoration applications for Federal Register concerning each
CFR 60.30), any interested person may
BLINCYTO (U.S. Patent Nos. 7,112,324 proposed collection of information,
petition FDA for a determination
and 8,007,796) from Amgen Research including each proposed reinstatement
regarding whether the applicant for
(Munich) GMBH, and the USPTO of an existing collection of information,
extension acted with due diligence and to allow 60 days for public
requested FDA’s assistance in during the regulatory review period. To
determining this patent’s eligibility for comment in response to the notice. This
meet its burden, the petition must notice solicits comments on the ‘‘Survey
patent term restoration. In a letter dated comply with all the requirements of
October 30, 2015, FDA advised the on the Occurrence of Foodborne Illness
§ 60.30, including but not limited to: Risk Factors in Selected Institutional
USPTO that this human biological must be timely (see DATES), must be
product had undergone a regulatory Foodservice and Retail Food Stores
filed in accordance with § 10.20, must Facility Types.’’
review period and that the approval of
contain sufficient facts to merit an FDA DATES: Submit either electronic or
BLINCYTO represented the first
permitted commercial marketing or use investigation, and must certify that a written comments on the collection of
of the product. Thereafter, the USPTO true and complete copy of the petition information by April 9, 2018.
requested that FDA determine the has been served upon the patent ADDRESSES: You may submit comments
product’s regulatory review period. applicant. (See H. Rept. 857, part 1, 98th as follows. Please note that late,
Cong., 2d sess., pp. 41–42, 1984.) untimely filed comments will not be
II. Determination of Regulatory Review Petitions should be in the format considered. Electronic comments must
Period specified in 21 CFR 10.30. be submitted on or before April 9, 2018.
FDA has determined that the Submit petitions electronically to The https://www.regulations.gov
applicable regulatory review period for https://www.regulations.gov at Docket electronic filing system will accept
BLINCYTO is 2,850 days. Of this time, No. FDA–2013–S–0610. Submit written comments until midnight Eastern Time
2,774 days occurred during the testing at the end of April 9, 2018. Comments
petitions (two copies are required) to the
phase of the regulatory review period, received by mail/hand delivery/courier
Dockets Management Staff (HFA–305),
while 76 days occurred during the (for written/paper submissions) will be
Food and Drug Administration, 5630
approval phase. These periods of time considered timely if they are
were derived from the following dates: Fishers Lane, Rm. 1061, Rockville, MD
postmarked or the delivery service
1. The date an exemption under 20852.
acceptance receipt is on or before that
section 505(i) of the Federal Food, Drug, Dated: January 31, 2018. date.
and Cosmetic Act (21 U.S.C. 355(i)) Leslie Kux,
became effective: February 15, 2007. Electronic Submissions
Associate Commissioner for Policy.
FDA has verified the applicant’s claims Submit electronic comments in the
[FR Doc. 2018–02419 Filed 2–6–18; 8:45 am]
that the date the investigational new following way:
drug application became effective was BILLING CODE 4164–01–P • Federal eRulemaking Portal:
on February 15, 2007. https://www.regulations.gov. Follow the
2. The date the application was instructions for submitting comments.
sradovich on DSK3GMQ082PROD with NOTICES
initially submitted with respect to the Comments submitted electronically,
human biological product under section including attachments, to https://
351 of the Public Health Service Act (42 www.regulations.gov will be posted to
U.S.C. 262): September 19, 2014. FDA the docket unchanged. Because your
has verified the applicant’s claim that comment will be made public, you are
the biologics license application (BLA) solely responsible for ensuring that your
for BLINCYTO (BLA 125557) was comment does not include any
VerDate Sep<11>2014 18:17 Feb 06, 2018 Jkt 244001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\07FEN1.SGM 07FEN1](https://thefederalregister.org/doc/83_FR_5467/page/1.svg)
![Federal Register / Vol. 83, No. 26 / Wednesday, February 7, 2018 / Notices 5445
collectors while they complete Sections estimate for a data collection in health 2 percent for the data collections within
1 and 3 of the form. FDA estimates that care facility types is 180 minutes (150 health care, school, and retail food store
it will take the program director (or + 30) (3 hours), in schools is 150 facility types. The estimate of the time
designated individual) of the respective minutes (120 + 30) (2.5 hours), and per non-respondent is 5 minutes (0.08
regulatory authority 30 minutes (0.5 retail food stores is 210 minutes (180 + hours) for the person in charge to listen
hours) to answer the questions related to 30) (3.5 hours). to the purpose of the visit and provide
Section 2 of the form. This burden Based on the number of entry refusals a verbal refusal of entry.
estimate is unchanged from the last data from the 2015–2016 baseline data FDA estimates the burden of this
collection. Hence, the total burden collection, we estimate a refusal rate of collection of information as follows:
TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of Number of
Number of Total annual Average
Number of responses Total annual responses Total
Activity non- non- burden per
respondents per responses per non- hours
respondents responses response
respondent respondent
2019–2020 Data Collection (Health Care 400 1 400 .................... .................... .................... 2.5 ........................ 1,000
Facilities)—Completion of Sections 1
and 3.
2019–2020 Data Collection (Schools)— 400 1 400 .................... .................... .................... 2 ........................... 800
Completion of Sections 1 and 3.
2019–2020 Data Collection (Retail Food 400 1 400 .................... .................... .................... 3 ........................... 1,200
Stores)—Completion of Sections 1 and
3.
2019–2020 Data Collection-Completion of 1,200 1 1,200 .................... .................... .................... .5 (30 minutes) ..... 600
Section 2—All Facility Types.
2019–2020 Data Collection-Entry Refus- .................... .................... .................... 24 1 24 .08 (5 minutes) ..... 1.92
als—All Facility Types.
Total .................................................... .................... .................... .................... .................... .................... .................... ............................... 3,601.92
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
The burden for this information 20170406023004/https://www.fda.gov/ Group, Microbiology and Infectious
collection has not changed since the last Food/GuidanceRegulation/RetailFood Diseases Research Committee.
OMB approval. Protection/FoodborneIllnessRiskFactor
Reduction/ucm224321.htm. The meeting will be closed to the
II. References 4. FDA National Retail Food Team. ‘‘FDA public in accordance with the
The following references are on
Trend Analysis Report on the provisions set forth in sections
Occurrence of Foodborne Illness Risk 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
display in the Dockets Management Factors in Selected Institutional
Staff (see ADDRESSES) and are available as amended. The grant applications and
Foodservice, Restaurant, and Retail Food
for viewing by interested persons Store Facility Types (1998–2008).’’
the discussions could disclose
between 9 a.m. and 4 p.m., Monday Available at: https://wayback.archive- confidential trade secrets or commercial
through Friday; they are also available it.org/7993/20170406022950/https:// property such as patentable material,
electronically at https:// www.fda.gov/Food/GuidanceRegulation/ and personal information concerning
www.regulations.gov. FDA has verified RetailFoodProtection/Foodborne individuals associated with the grant
IllnessRiskFactorReduction/ applications, the disclosure of which
the website addresses, as of the date this ucm223293.htm.
document publishes in the Federal would constitute a clearly unwarranted
5. ‘‘FDA Food Code.’’ Available at: https://
Register, but websites are subject to www.fda.gov/Food/GuidanceRegulation/ invasion of personal privacy.
change over time. RetailFoodProtection/FoodCode/ Name of Committee: Microbiology,
1. ‘‘Report of the FDA Retail Food Program default.htm. Infectious Diseases and AIDS Initial Review
Database of Foodborne Illness Risk Dated: January 31, 2018. Group; Microbiology and Infectious Diseases
Factors’’ (2000). Available at: https:// Leslie Kux, Research Committee.
wayback.archive-it.org/7993/201704 Date: March 1–2, 2018.
Associate Commissioner for Policy.
06023019/https://www.fda.gov/ Time: 8:00 a.m. to 5:00 p.m.
downloads/Food/GuidanceRegulation/ [FR Doc. 2018–02413 Filed 2–6–18; 8:45 am]
Agenda: To review and evaluate grant
UCM123546.pdf. BILLING CODE 4164–01–P
applications.
2. ‘‘FDA Report on the Occurrence of
Place: National Institutes of Health, 5601
Foodborne Illness Risk Factors in
Selected Institutional Foodservice, Fishers Lane, Rockville, MD 20892
DEPARTMENT OF HEALTH AND
Restaurant, and Retail Food Store (Telephone Conference Call).
HUMAN SERVICES
Facility Types’’ (2004). Available at: Contact Person: Frank S. De Silva, Ph.D.,
https://wayback.archive-it.org/7993/ National Institutes of Health Scientific Review Officer, Scientific Review
20170406023011/https://www.fda.gov/ Program, Division of Extramural Activities,
downloads/Food/GuidanceRegulation/ National Institute of Allergy and Room #3E72A, National Institutes of Health/
RetailFoodProtection/Foodborne NIAID, 5601 Fishers Lane, MSC 9834,
sradovich on DSK3GMQ082PROD with NOTICES
Infectious Diseases; Notice of Closed
IllnessRiskFactorReduction/ Meeting Bethesda, MD 20892–934, (240) 669–5023,
UCM423850.pdf. fdesilva@niaid.nih.gov.
3. ‘‘FDA Report on the Occurrence of
Foodborne Illness Risk Factors in
Pursuant to section 10(d) of the (Catalogue of Federal Domestic Assistance
Selected Institutional Foodservice, Federal Advisory Committee Act, as Program Nos. 93.855, Allergy, Immunology,
Restaurant, and Retail Food Store amended, notice is hereby given of a and Transplantation Research; 93.856,
Facility Types’’ (2009). Available at: meeting of the Microbiology, Infectious Microbiology and Infectious Diseases
https://wayback.archive-it.org/7993/ Diseases and AIDS Initial Review Research, National Institutes of Health, HHS)
VerDate Sep<11>2014 18:17 Feb 06, 2018 Jkt 244001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\07FEN1.SGM 07FEN1](https://thefederalregister.org/doc/83_FR_5467/page/5.svg)
Document Created: 2018-10-26 13:56:16
Document Modified: 2018-10-26 13:56:16
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | Submit either electronic or written comments on the collection of information by April 9, 2018. | |
| Contact | Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, [email protected] | |
| FR Citation | 83 FR 5441 |
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR